Echopoint Medical
London, GB Β· Founded 2018 Β· 18 employees on LinkedIn Β· 4 known investors
Echopoint Medical develops cardiac technology focused on coronary physiology for interventional cardiology. The company works in the medical device space for cardiovascular care.
Also known as EchoPoint Medical Β· Echopoint Medical Ltd
Founders & leadership
Echopoint Medical was founded in 2018 by Malcolm Charles Finlay, Antony Ruben Odell, Antony Odell, Malcolm Finlay, and Adrien Desjardins.
Investors Β· 4
Funding
SEC filings, press & company announcements$250K disclosed across 1 of 3 rounds Β· 2024β2026
- Undisclosed amountSeries AMay 2024 Β· 2 sources
Parkwalk Advisors (lead), UCL Technology Fund (lead), AlbionVC
Source β
βΆ$250KraisedDec 2025 Β· 3 investors Β· Other Health CareRule 506(b)
- Malcolm Charles FinlayDirector
- Priscila HancockExecutive Officer
- Weng Sie WongDirector
- Nancy BriefsDirector
- Antony Ruben OdellExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Nov 2025
- Incorporated
- Limited Liability Company, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Echopoint Medical is a London-based medical technology company spun out of University College London. It develops the iKOr microcatheter system, a diagnostic device intended to give interventional cardiologists a complete picture of coronary physiology during catheterisation procedures. The system is designed to measure coronary flow reserve (CFR), the index of microcirculatory resistance (IMR), diastolic flow indices, and continuous relative flow and resistance data, producing a full physiological profile within minutes.
The product is positioned for use in existing cath lab workflows: it uses a rapid-exchange microcatheter design compatible with a workhorse guidewire, allowing sequential readings before and after interventions without exchanging guidewires, and is presented as requiring minimal training. The company frames the clinical need around conditions such as ANOCA (angina with non-obstructive coronary arteries), where distinguishing microvascular dysfunction from coronary spasm requires more complete physiological data, and around the underdiagnosis of cardiovascular disease in women.
External profiling describes the company as a medical device and medical imaging business applying fibre-optic sensing technology to cardiovascular devices for minimally invasive procedures, selling hardware on a B2B basis.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 14
launches, deals, and filingsEchopoint Medical announced a $2.5M investment round led by Parkwalk with participation from UCL Technology Fund, intended to fund progress toward an FDA submission and the start of a US clinical program for the iKOr system.
$2.5M source β
The company reported progress toward the iKoDE clinical study addressing the ANOCA/INOCA diagnostic gap.
Echopoint Medical joined a cardiovascular accelerator program; Caplight lists an accelerator round dated 7 October 2025 with HTA and HeartX Accelerator.
The company announced a Β£4.2 million Series A round to advance the FDA approval process for the iKOr system.
The company began its first-in-human study at Barts Heart Centre in London; the milestone received coverage in the Financial Times.
Echopoint Medical completed a first-in-human trial of the iKOr microcatheter system.
Echopoint Medical obtained regulatory approval from the Medicines and Healthcare products Regulatory Agency for a first-in-human study in the United Kingdom.
The company reports being awarded a Smart Grant, a Precision Medicine Award and a Biomedical Catalyst Award from Innovate UK.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities Β· 1
corporate structureCompanies House Β· registry record
View on Companies House β- Registered name
- ECHOPOINT MEDICAL LTD
- Company number
- 11669397
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 9 Nov 2018
- Registered office
- 2nd Floor 65-69 East Road, London, N1 6AH
- Nature of business (SIC)
- 32500 β Manufacture of medical and dental instruments and supplies
- Accounts
- last made up to 31 Dec 2025 Β· next due 30 Sept 2027
- Confirmation statement
- last made up to 1 Jul 2026 Β· next due 15 Jul 2027
Current officers Β· 5
- Nancy Briefs β director, appointed 1 Oct 2024
- Malcolm Charles Finlay β director, appointed 9 Nov 2018
- Antony Ruben Odell β director, appointed 9 Nov 2018
- Parkwalk Advisors Ltd β corporate director, appointed 18 Jul 2019
- Ucltf Corporate Directors Ltd β corporate director, appointed 19 Feb 2024
Source: Companies House public register Β· retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
βΈResearch sources Β· 8
primary sources listed
- Echopoint Medicalechopointmedical.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Echopoint Medical do?
- UCL spinout developing the iKOr microcatheter system for comprehensive coronary physiology assessment in the cath lab.
- Who founded Echopoint Medical?
- Echopoint Medical was founded by Malcolm Charles Finlay, Antony Ruben Odell, Antony Odell, Malcolm Finlay, Adrien Desjardins in 2018.
- Who are Echopoint Medical's investors?
- Echopoint Medical's investors include UCL Technology Fund, Queen Mary University of London, AlbionVC, Parkwalk Advisors.
- How much funding has Echopoint Medical raised?
- Echopoint Medical has disclosed $250K raised across 1 of its 3 known rounds.
- Where is Echopoint Medical headquartered?
- Echopoint Medical is headquartered in London, GB.